Immatics N.v. · NASDAQ:IMTX
Immatics — Society of Melanoma Research Congress 2024
28 slides from Immatics's conference presentation, Oct 10, 2024
Slide 1: ACTengine IMA203 Targeting PRAME in PD1 Refractory Metastatic Melanoma - Phase 1b Dose Expansion
ACTengine® IMA203 TCR - T Targeting PRAME in PD1 Refractory Metastatic Melanoma - Phase 1b Dose Expansion Clinical Data Update October 10, 2024 Oral presentation by Martin Wermke at the Society of Melanoma Research Congress on October 11, 2024 Data cut - off Aug 23, 2024 Delivering the Power of T ce
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: PRAME – A Widely Expressed Cancer Testis Antigen
PRAME – A Widely Expressed Cancer Testis Antigen 3 100 100 µm 81 90 % PRAME+ cells PRAME RNA Detection in Melanoma Samples (ISH) % PRAME Positive Patients in Selected Indications Uterine Carcinosarcoma Sarcoma Subtypes Uterine Carcinoma Cut. Melanoma Uveal Melanoma 1 Ovarian Carcinoma Squamous NSCLC
Slide 4: ACTengine IMA203 Monotherapy – Patient Flow
ACTengine® IMA203 TCR - T Monotherapy – Patient Flow 4 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Low dose IL - 2 ** Safety
Slide 5: ACTengine IMA203 Trial in Melanoma Heavily Pretreated Patient Population
ACTengine® IMA203 TCR - T Trial in Melanoma Heavily Pretreated Patient Population 5 Data cut - off Aug 23, 2024 1 See patient flow in appendix. 2 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints, see appendix; RP2D: recommended phase 2 dose; CPI: Checkp
Slide 6: Most Frequent Adverse Events of IMA203 Across All Dose Levels
6 Data cut - off Aug 23, 2024 • Most frequent adverse events were expected cytopenias (Grade 1 - 4) associated with lymphodepletion in all patients • Mostly mild to moderate cytokine release syndrome (CRS) • 37% (26/70) Grade 1 • 46% (32/70) Grade 2 • 11% (8/70) Grade 3 2 • Infrequent ICANS (6% Grad
Slide 7: Best Overall Response for IMA203 in Melanoma
Best Overall Response for IMA203 in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28 # ) 7 Data cut - off Aug 23, 2024 ongoi n g # First tumor assessment post infusion pending for two melanoma patients at data - cut; * Maximum change of target lesions and RECIST1.1 respo
Slide 8: Response Over Time of IMA203 in Melanoma
Response Over Time of IMA203 in Melanoma Durable Responses 2 Years+ after Treatment in Heavily Pretreated Patients in Phase 1b (N=28 # ) 8 Ongoing Scans at approximately week 6, month 3 and then every 3 months Data cut - off Aug 23, 2024 # First tumor assessment post infusion pending for two melanom
Slide 9: Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion
Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS Not Reached in Melanoma Efficacy Population 9 Progression Free Survival Data cut - off Aug 23, 2024 Overall Survival Overall survival (OS) and progression - free survival (PFS) censored at data - cut; * T
Slide 10: IMA203 Phase 1b in Melanoma: Overview of Studies
IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in 2L+ Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies 2L+ melanoma patient population N Phase Drug Product not reached 6.0 4% n=0, 18% n=1, 32% n=2, 29% n=3:, 4% n=4, 11% n=5, 4% n=6 86% received prior CPI (median
Slide 11: Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses
Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses N=26 # 11 • Approx. half of all patients have a deep response (>50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase
Slide 12: Dose Response Relationship
0 5 î 10 5 1 î 10 6 1.5 î 10 6 2 î 10 6 2.5 î 10 6 Cmax (vector copies/μg gDNA) 4 6 8 10 Infused Total (CD8 + Dex + ) IMA203 T cell dose (x10 9 ) 2 1 0 Dose Response Relationship IMA203 T Cell Dose is Associated with Clinical Activity and IMA203 T Cell Exposure (N=65 out of 68*) 12 RP2D cPR (n=23) P
Slide 13: Exposure Response Relationship
Exposure Response Relationship IMA203 T Cell Persistence Over Time and T Cell Exposure is Associated with Clinical Response 13 Rapid T cell engraftment (C max ) in all patients with over two years of persistence Higher C max and persistence in patients treated at higher doses in dose expansion versu
Slide 14: Patient Case A-DL4: Cutaneous Melanoma
Patient Case A - DL4 - 03 : Cutaneous Melanoma 14 Images courtesy of treating physician (Dr. Martin Wermke, University of Dresden) PET - based Complete Response 15 Months Post Infusion and Ongoing Response at 24 Months 51 - year - old male patient with complete remission according to PET imaging aft
Slide 15: SUPRAME: Registration-enabling Randomized Phase 3 Trial
SUPRAME: Registration - enabling Randomized Phase 3 Trial Trial Design Following Recent Type D Meeting with FDA and SA Meeting with PEI 1 15 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=1 8 0 Endpoints • Primary Endpoint • PFS • Secondary Endpoints • Safety • ORR +
Slide 16: ACTengine IMA203 Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data
ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data Tolerability PFS & OS Biological Data Broad Reach Favorable tolerability profile: mostly mild to moderate CRS; infrequent ICANS (5.7% Gr1, 4.3% Gr2, 4.3% Gr3); no treatment related deaths Anti - Tumor Activity
Slide 17: We are Immensely Grateful to the Patients, Their Families
17 We are Immensely Grateful to the Patients, Their Families … University Hospital Dresden University Hospital Bonn University Hospital Würzburg University Hospital Hamburg Ge r ma n y Dr. M. Wermke Charité Berlin University Hospital Heidelberg University Medicine Mainz Columbia U n iv e rsity Unive
Slide 18: Appendix
a) immiatics Appendix
Slide 19: Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b
Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b All ≥Grade 3 Adverse Events (N=70 1 ) TEAEs by maximum severity for all patients in Phase 1a and Phase 1b (N=70 1 ) Data cut - off Aug 23, 2024 19 ≥ Grade 3 Adverse event ( System organ class , Preferred term) % No. 100.0 70 Patient
Slide 20: IMA203 Phase 1 Patient Population Flow Chart
IMA203 Phase 1 Patient Population Flow Chart 20 Data cut - off Aug 23, 2024 * Melanoma efficacy population excludes 5 patients treated at DL4 in Phase 1a of the trial as reported in the May 2024 update, based on different manufacturing version used that affects the T cell product (see slide 22); Cur
Slide 21: Baseline Characteristics of Melanoma Patients in Phase 1a and Phase 1b
Baseline Characteristics of Melanoma Patients in Phase 1a and Phase 1b Focus on Cutaneous and Uveal Melanoma Melanoma Efficacy Population 1 Melanoma Dose Escalation Population Uveal Melanoma (N=12) Cutaneous Melanoma (N=13) Uveal Melanoma (N=2) Cutaneous Melanoma (N=8) Indication 2.5 (0, 6) 1 (0, 4)
Slide 22: Favorable Product Characteristics and High Levels in Patients
Favorable TCR - T Product Characteristics and High TCR - T Levels in Patients Manufacturing Improvements Implemented in Phase 1b Enhance Key Features of the Cell Product 22 Robust TCR - T product features Increased peak IMA203 T cell levels in patients DL4 only, normalized to cell dose Data cut - of
Slide 23: T Cell Selection Results in 'Younger' Phenotype of the Product
T Cell Selection Results in ‘Younger’ Phenotype of the TCR - T Product Consequently, Terminally Differentiated T Cells are also Decreased 23 L = Low enrichment (n=7, prior manufacturing version) M = Medium enrichment (n=37, current manufacturing version) H = High enrichment (n=38, current manufactur
Slide 24: Melanoma Patients Treated with IMA203 in Phase 1b Dose Expansion
Melanoma Patients Treated with IMA203 in Phase 1b Dose Expansion Efficacy - evaluable Population (n=28*) Reason for Progression Comment BOR (Max % change of target lesions) B OR Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior treatment lines Indication Patient ID Ongoing res
Slide 25: Melanoma Patients Treated with IMA203 in Phase 1b Dose Expansion (continued)
Reason for Progression Comment BOR (Max % change of target lesions) BOR Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior treatment lines Indication Patient ID New lesions Disease stabilization until 2.7 months post infusion, unconfirmed response from 2.7 until 5.5 months PFS
Slide 26: Patient Case A-DL5-01: Uveal Melanoma Long-term Responder
Patient Case A - DL5 - 01: Uveal Melanoma Long - term Responder Ongoing at 26+ Months B a seline Follow - up Month 1 - 51% PR Follow - up Month 26 - 83% PR 71 - year - old male patient with ongoing shrinkage of liver lesion 26+ months post treatment • 1 prior line of systemic treatment: ARRY614 + Ni
Slide 27: Patient Case A-DL5-033: Cutaneous Melanoma
Patient Case A - DL5 - 033: Cutaneous Melanoma Changes of a Melanoma Lesion of the Skin within 8 Days (Post Data Cut - off) Data cut Aug 23, 2024; Patient was treated post data cut - off date (Aug 26, 2024); Images courtesy of treating physician (Dr. Jason Luke, University of Pittsburgh) Follow - up
Slide 28: Delivering the Power of T cells to Cancer Patients
Deli v ering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. www.immatics.com
Immatics — Society of Melanoma Research Congress 2024 on 6ix